OncoMatch/Clinical Trials/NCT07174908
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Is NCT07174908 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including IN10018 in combination with D-1553 and anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed for non-small cell lung cancer.
Treatment: IN10018 in combination with D-1553 · anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed — This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: KRAS g12c
Required: ROS1 wild-type
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS inhibitor
Prior treatment with KRAS G12C inhibitors
Cannot have received: FAK inhibitor
Prior treatment with FAK inhibitors
Cannot have received: checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors
Lab requirements
Blood counts
Kidney function
Liver function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify